Literature DB >> 6652021

The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in vitro and in vivo studies.

N J Bradley, J L Darling, N Oktar, H J Bloom, D G Thomas, A J Davies.   

Abstract

Five high-grade (3 grade III and 2 grade IV) astrocytoma tumour cell populations were treated with a preparation of Human Leukocyte Interferon either in monolayer cell culture or as multicellular spheroids in vitro or as xenografts growing in immune-deprived mice in vivo. A moderate and transient sensitivity was seen in one grade III tumour when tested in both of the in vitro assays, but no inhibition of growth was seen in vivo. Two tumours which were apparently resistant to Interferon treatment responded to orthodox chemotherapy. When used in conjunction with BCNU, Interferon was not effective in prolonging delay in tumour growth. It is concluded that Interferon is unlikely to be an effective agent in the treatment of malignant brain tumours.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652021      PMCID: PMC2011555          DOI: 10.1038/bjc.1983.272

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Growth inhibitory effects of interferon on normal and malignant human haemopoietic cells.

Authors:  F R Balkwill; R T Oliver
Journal:  Int J Cancer       Date:  1977-10-15       Impact factor: 7.396

2.  A simplified method for production and growth of multicellular tumor spheroids.

Authors:  J M Yuhas; A P Li; A O Martinez; A J Ladman
Journal:  Cancer Res       Date:  1977-10       Impact factor: 12.701

3.  Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection.

Authors:  G W Jordan; R P Fried; T C Merigan
Journal:  J Infect Dis       Date:  1974-07       Impact factor: 5.226

4.  Mechanism of the antitumour effect of interferon in mice.

Authors:  I Gresser; C Maury; D Brouty-Boyé
Journal:  Nature       Date:  1972-09-15       Impact factor: 49.962

5.  Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes.

Authors:  P Lindahl; P Leary; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

6.  Cellular binding characteristics of human interferon.

Authors:  B Berman; J Vilcek
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

7.  Clinical studies in malignant gliomas and their treatment with the nitrosoureas.

Authors:  M D Walker; E A Gehan
Journal:  Cancer Treat Rep       Date:  1976-06

8.  Effects of interferon on cell and virus growth in transformed human cell lines.

Authors:  T K Fuse; N Morinaga
Journal:  J Gen Virol       Date:  1976-10       Impact factor: 3.891

9.  Variation in response of xenografts of colo-rectal carcinoma to chemotherapy.

Authors:  K Nowak; M J Peckham; G G Steel
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640

10.  Growth of human gliomas in immune-deficient mice: a possible model for pre-clinical therapy studies.

Authors:  N J Bradley; H J Bloom; A J Davies; S M Swift
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640

View more
  10 in total

1.  Local immunotherapy (beta-IFN) and systemic chemotherapy in primary glial tumors.

Authors:  A Boiardi; A Silvani; I Milanesi; L Munari; G Broggi; M Botturi
Journal:  Ital J Neurol Sci       Date:  1991-04

2.  An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tumour necrosis factor.

Authors:  G Unsgaard; E Helseth; R Vik; A Dalen
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

3.  The effects of interferon on glial cells.

Authors:  M R Stratton; J M Martin; P L Lantos
Journal:  Br J Exp Pathol       Date:  1987-10

4.  Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.

Authors:  W K Yung; P A Steck; P J Kelleher; R P Moser; M G Rosenblum
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

5.  Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines.

Authors:  J I Garrison; M E Berens; J R Shapiro; S Treasurywala; G Floyd-Smith
Journal:  J Neurooncol       Date:  1996-12       Impact factor: 4.130

6.  Sensitivities of human glioma cell lines to interferons and double-stranded RNAs individually and in synergistic combinations.

Authors:  R S Dick; H R Hubbell
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

7.  Interferon-beta in patients with low-grade astrocytomas--a phase I study.

Authors:  U Bogdahn; B Fleischer; J Hilfenhaus; H J Röthig; P Krauseneck; H G Mertens; H Przuntek
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

8.  Human non-malignant and malignant brain tumor derived cell cultures: proliferation and sensitivity to natural human fibroblast (beta) interferon.

Authors:  A W Cook; F Nidzgorski; P R Roane; G Mann; P Came; W A Carter
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

9.  The chemotherapeutic response of a murine (VM) model of human glioma.

Authors:  R Bradford; J L Darling; D G Thomas
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

10.  Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma.

Authors:  A D Arslan; A Sassano; D Saleiro; P Lisowski; E M Kosciuczuk; M Fischietti; F Eckerdt; E N Fish; L C Platanias
Journal:  Oncogene       Date:  2017-07-03       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.